Gallengangskarzinome – up to date in Diagnostik und Therapie

Gallengangskarzinome sind eine heterogene Gruppe seltener Tumorentitäten, die mit einer hohen Mortalität vergesellschaftet sind. Die Behandlung benötigt in der Regel ein hohes Maß an Interdisziplinarität. Insbesondere in den letzten Jahren konnten aber in der zielgerichteten medikamentösen Therapie neue Meilensteine erreicht werden. Dieser Beitrag beschreibt Grundlagen, Diagnostik und aktuelle Therapiestandards der Gallengangskarzinome.

Schlüsselwörter

Gallengangskarzinome - cholangiozelluläre Karzinome - biliäre Karzinome - Gallengangskrebs

• Literatur

• 1 Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol 2023; 107064
• 2 Walter D, Ferstl P, Waidmann O. et al. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification. Liver Int 2019; 39: 316-323
• 3 Robert Koch-Institut Krebsregisterdaten. Krebs der Gallenblase und Gallenwege. Accessed April 08, 2024 at: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Gallenblasenkrebs/gallenblasenkrebs_node.html
• 4 Banales JM, Marin JJG, Lamarca A. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020; 17: 557-588
• 5 Bitzer M, Groß S, Albert J. et al. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion. Z Gastroenterol 2023; 61: e92-e156
• 6 Nakanuma Y, Kakuda Y, Sugino T. et al. Pathologies of Precursor Lesions of Biliary Tract Carcinoma. Cancers (Basel) 2022; 14: 5358
• 7 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-1229
• 8 Morgan MA, Khot R, Sundaram KM. et al. Primary sclerosing cholangitis: review for radiologists. Abdom Radiol (NY) 2023; 48: 136-150
• 9 Eaton JE, Welle CL, Bakhshi Z. et al. Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology 2021; 73: 1868-1881
• 10 Rizvi S, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol 2015; 13: 2152-2165
• 11 Forner A, Vidili G, Rengo M. et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019; 39 (Suppl. 1) 98-107
• 12 Vogel A, Bridgewater J, Edeline J. et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 127-140
• 13 Bitzer M, Gross S, Albert J. et al. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome. Z Gastroenterol 2023; 61: 420-440
• 14 Ke C, Yang T, Huang G. et al. Investigation of the accuracy of magnetic resonance cholangiography and multi-slice spiral computed tomography in the diagnosis of cholangiocarcinoma. J Gastrointest Oncol 2023; 14: 1496-1503
• 15 Bitzer M, Gross S, Albert J. et al. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome. Z Gastroenterol 2023; 61: e92-e156
• 16 Matsuo K, Rocha FG, Ito K. et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 2012; 215: 343-355
• 17 Navaneethan U, Njei B, Venkatesh PG. et al. Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf) 2015; 3: 209-215
• 18 Otto CC, Mantas A, Heij LR. et al. Preoperative predictors for non-resectability in perihilar cholangiocarcinoma. World J Surg Oncol 2024; 22: 48
• 19 Kawashima J, Sahara K, Shen F. et al. Predicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma. J Gastrointest Surg 2024; 28: 18-25
• 20 Song DJ, Zhu K, Tan JP. et al. Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis. Surg Endosc 2023; 37: 967-976
• 21 Cillo U, Fondevila C, Donadon M. et al. Surgery for cholangiocarcinoma. Liver Int 2019; 39 (Suppl. 1) 143-155
• 22 Chang Y, Li Q, Wu Q. et al. Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases. World J Surg Oncol 2020; 18: 142
• 23 Kim KM, Park JW, Lee JK. et al. A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic versus Percutaneous Transhepatic Biliary Drainage. Gut Liver 2015; 9: 791-799
• 24 Mohammad T, Kahaleh M. Comparing palliative treatment options for cholangiocarcinoma: photodynamic therapy vs. radiofrequency ablation. Clin Endosc 2022; 55: 347-354
• 25 Bisello S, Camilletti AC, Bertini F. et al. Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review. Mol Clin Oncol 2021; 15: 152
• 26 Primrose JN, Fox RP, Palmer DH. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20: 663-673
• 27 Bridgewater J, Fletcher P, Palmer DH. et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol 2022; 40: 2048-2057
• 28 Oh DY, Ruth He A, Qin S. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid 2022; 1: EVIDoa2200015
• 29 Kelley RK, Ueno M, Yoo C. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401: 1853-1865
• 30 Malka D, Cervera P, Foulon S. et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15: 819-828
• 31 Phelip JM, Desrame J, Edeline J. et al. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. J Clin Oncol 2022; 40: 262-271
• 32 Yoo C, Kim KP, Jeong JH. et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021; 22: 1560-1572
• 33 Subbiah V, Lassen U, Elez E. et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020; 21: 1234-1243
• 34 Abou-Alfa GK, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21: 671-684
• 35 Goyal L, Meric-Bernstam F, Hollebecque A. et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med 2023; 388: 228-239
• 36 Javle M, Borad MJ, Azad NS. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021; 22: 1290-1300
• 37 Lee CK, Chon HJ, Cheon J. et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14). Lancet Gastroenterol Hepatol 2023; 8: 56-65
• 38 Abou-Alfa GK, Macarulla T, Javle MM. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 796-807
• 39 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38: 1-10